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A B S T R A C T
Previous work from our group showed that tamoxifen, an oral drug that has been in use for the treatment of
breast cancer for over 40 years, is active both in vitro and in vivo against several species of Leishmania, the
etiological agent of leishmaniasis. Using a combination of metabolic labeling with [3H]-sphingosine and myo-
[3H]-inositol, alkaline hydrolysis, HPTLC fractionations and mass spectrometry analyses, we observed a per-
turbation in the metabolism of inositolphosphorylceramides (IPCs) and phosphatidylinositols (PIs) after treat-
ment of L. amazonensis promastigotes with tamoxifen, with a significant reduction in the biosynthesis of the
major IPCs (composed of d16:1/18:0-IPC, t16:0/C18:0-IPC, d18:1/18:0-IPC and t16:0/20:0-IPC) and PIs (sn-1-O-
(C18:0)alkyl -2-O-(C18:1)acylglycerol-3-HPO4-inositol and sn-1-O-(C18:0)acyl-2-O-(C18:1)acylglycerol-3-HPO4-in-
ositol) species. Substrate saturation kinetics of myo-inositol uptake analyses indicated that inhibition of inositol
transport or availability were not the main reasons for the reduced biosynthesis of IPC and PI observed in
tamoxifen treated parasites. An in vitro enzymatic assay was used to show that tamoxifen was able to inhibit the
Leishmania IPC synthase with an IC50 value of 8.48 μM (95% CI 7.68–9.37), suggesting that this enzyme is most
likely one of the targets for this compound in the parasites.
1. Introduction
Leishmania spp. are the etiological agent of leishmaniasis, a group of
vector-borne neglected disease affecting approximately 12 million
people worldwide with 1.2 million new cases per year (Reithinger et al.,
2007; Alvar et al., 2012). Taken together they show a spectrum of
clinical manifestations, ranging from self-healing cutaneous forms to
fatal visceral leishmaniasis in endemic areas. This clinical diversity
depends on parasite species, host immunity and genetics, amongst other
factors (Reithinger et al., 2007; WHO, 2010). Leishmania (Leishmania)
amazonensis is one of the most prevalent species causing human cuta-
neous leishmaniasis (CL) and the main etiological agent responsible for
diffuse cutaneous leishmaniasis (DCL) in South America. DCL is char-
acterized by multiple lesions with uncontrolled progression of infection
and poor or absent response to chemotherapy due to host defective
parasite-specific cell mediated immunity (Convit and Ulrich, 1993).
Only a few drugs are available for leishmaniasis treatment. These
drugs are in general expensive, toxic and of systemic administration,
and therapeutic failure is a problem in endemic areas (Croft and
Coombs, 2003; Alvar et al., 2006). Against this background, drug re-
purposing is an attractive option for the discovery for new antil-
eishmanials (Charlton et al., 2018).
Tamoxifen, an oral drug that has been in use for the treatment of
breast cancer for over 40 years (Jordan, 2003), has been shown to be
active against several species of Leishmania in vitro (Miguel et al., 2007)
and in vivo (Miguel et al., 2008, 2009). It has also been shown to be a
good partner when used in combination with amphotericin B (Trinconi
et al., 2014), miltefosine (Trinconi et al., 2016) and meglumine anti-
moniate (Trinconi et al., 2017) in an established CL animal model. In
many different lineages of human cancer cells tamoxifen has been
proven to be a multi-target drug interfering in distinct cell pathways,
such as sphingolipid (SL) metabolism (Cabot et al., 1996). SLs are es-
sential cell membrane components in eukaryotic organisms (Mina and
Denny, 2018), including protozoa of the Trypanosomatidae family such
as Leishmania (Kaneshiro et al., 1986; Denny et al., 2004; Sutterwala
et al., 2008). SLs act as important mediators of cell signaling and
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control several critical and important cell biology processes, including
endocytosis, cell growth, differentiation, apoptosis, and oncogenesis
(Shayman, 2000). The most abundant SL in Leishmania is inositolpho-
sphorylceramide (IPC), corresponding to 5–10% of membrane total li-
pids (Kaneshiro et al., 1986) and abundantly present in membrane
fractions known as lipid rafts (Yoneyama et al., 2006). IPC is also
abundant in yeast (Shayman, 2000), Trypanosoma cruzi and Trypano-
soma brucei (Figueiredo et al., 2005; Sutterwala et al., 2008). IPC syn-
thase activity has been shown to be essential for S. cerevisiae survival
(Nagiec et al., 1997) and T. brucei blood forms (Sutterwala et al., 2008;
Mina et al., 2009). Mammalians do not synthetize IPC, with pre-
dominance of sphingomyelin (SM) instead (Merrill, 2011). IPC abun-
dance in Leishmania and its absence in mammalian cells (Denny and
Smith, 2004) suggest that the enzyme responsible for its synthesis, IPC
synthase (Denny et al., 2006), might be a good target for therapeutic
intervention. Remarkably, tamoxifen's activity over sphingolipid (SL)
metabolism in cancer cells (Cabot et al., 1996) has been already de-
monstrated. These information prompted us to investigate whether this
could be part of its mechanism of action against Leishmania.
In the present work, we show that L. amazonensis promastigotes
treated with tamoxifen display a perturbation in SL metabolism with a
significant reduction of IPCs/PIs species, increased abundance of acyl
ceramide and direct inhibition of IPC synthase.
2. Material and methods
2.1. Parasites
L. amazonensis (MHOM/BR/73/M2269) promastigotes were culti-
vated in M-199 medium supplemented with 10% heat inactivated-fetal
calf serum (FCS), 25mM HEPES (pH 6.9), 12mM NaHCO3, 7.6mM
hemin, 50 U/mL penicillin, 50 μg/mL streptomycin at 25 °C.
2.2. Drug and lipid standards
Tamoxifen (T5648) was purchased from Sigma-Aldrich (St. Louis,
MO, USA). Stock solutions of tamoxifen (10mM) were prepared in
DMSO and kept at −20 °C. Subsequent dilutions were done in culture
media. d18:1/16:0 C16-ceramide (N-palmitoyl-D-erythro-sphingosine,
Avanti®Polar Lipids, Inc.), 18:1 PI [1,2-dioleoyl-sn-glycero-3-phosphoi-
nositol (ammonium salt), Avanti®Polar Lipids, Inc.] and acyl-ceramide
(1-oleoyl-N-heptadecanoyl-D-erythro-sphingosine, Avanti®Polar Lipids,
Inc.) were used as standards.
2.3. Metabolic labeling and lipid extraction
Metabolic labeling assays were performed with 8×108 L. amazo-
nensis stationary phase promastigotes. After washing twice with PBS
(137mM NaCl, 2.7 mM KCl, 10mM Na2HPO4, 1.8 mM KH2PO4),
parasites were suspended in PBS-glucose (1 g/L) at a cell density of
5× 107 cells/mL and treated with 10 μM tamoxifen during 4 h. Ninety
minutes after the start of the treatment, cells were labeled with 2–6 μCi
[3H]-sphingosine (Sphingosine, D-erythro-[3-3H], specific activity
18.4 Ci/mmol, PerkinElmer®, Boston, MA, USA) or 6 μCi myo-[3H]-in-
ositol (Inositol, myo-[2–3H(N)]-, specific activity 22.5 Ci/mmol,
PerkinElmer®, Boston, MA, USA) for 150min. Then, the cells were
washed three times with Hank's solution (137mM NaCl, 5.3mM KCl,
0.4 mM KH2PO4, 10mM glucose, 4.2mM NaHCO3 and 0.4mM
Na2HPO4, pH 7.2) to remove unincorporated radiolabeled precursors.
Lipid extraction from 4×108 promastigotes was performed as de-
scribed by Boath and coworkers with some modifications (Boath et al.,
2008). Briefly, parasites were mixed at 1100 rpm with 1.24mL of
1:1:0.75 (v/v/v) chloroform: methanol: ultra-pure water for 30min.
After centrifugation at 2×g during 10min, the organic phase was re-
served and the aqueous phase was re-extracted with 600 μL of chloro-
form. This procedure was repeated twice. The three organic phases
obtained were joined, dried under N2 gas and stored at −20 °C.
2.4. High performance thin layer chromatography (HPTLC)
The lipid fractions of parasites treated or not with tamoxifen were
analyzed by HPTLC. Lipid extracts were dissolved in 50 μL 1:1 (v/v)
chloroform: methanol and 10 μL were spotted onto HPTLC Silica gel 60
plate (Merck, Darmastadt, Germany). Extracts were run in four different
running systems: (1) 60:35:8 (v/v/v) chloroform:methanol:water
during the initial run covering 20% of the plate and 90:2:8 (v/v/v)
chloroform:methanol:acetic acid for the remaining of the plate (run-
ning system 1) (Ichikawa et al., 1994); (2) 60:35:8 (v/v/v) chlor-
oform:methanol:water for 50% of the plate and 90:2:8 (v/v/v) chlor-
oform:methanol:acetic acid for the remaining of the plate (running
system 2) (Ichikawa et al., 1994 modified); (3) 58:32:9.3 (v/v/v)
chloroform:methanol: methylamine 40% (running system 3) (Castro
et al., 2013) and (4) 40:40:12 (v/v/v) chloroform:methanol:water
(running system 4) (Martin and Smith, 2006). The migration patterns
of standards were analyzed after staining in iodine vapor. Labeled lipids
were visualized after spraying the plate with En3Hance® (PerkinElmer®)
followed by exposure to autoradiography film (Hyperfilm™ Amersham
ECL 18× 24 cm) (GE Healthcare) at – 80 °C for 3–30 days. Auto-
radiography images were scanned and analyzed using the software
ImageJ® (http://imagej.nih.gov/ij/). Intensity change was calculated
as: % Change=100 – [(Number of pixels treated sample area – number
of pixels blank area) x 100]/(Number of pixels control sample area –
number of pixels blank area). The percentage of intensity change on
abundance of lipids of interest is presented as mean and standard de-
viation of 3–5 independent performed experiments.
2.5. Lipid extraction from silica
Labeled and unlabeled lipid fractions of parasites treated or not with
tamoxifen were ran in parallel by HPTLC using running system 2.
Guided by the migration of labeled lipids of interest, the unlabeled li-
pids were scraped from the silica plate and extracted three times with
3mL 3:3:0.8 (v/v/v) chloroform:methanol:water followed by ultra-
sound treatment for 60 s in a water bath (VWR B2.500A Ultrasonic
Cleaner - DTH, North American VWR), homogenization in a magnetic
stirrer for 90min at room temperature and a second ultrasound treat-
ment for 60 s. The samples were centrifuged at 2600×g for 10min and
the organic phase transferred into a new tube. The three organic layers
were dried under N2 gas and stored at - 20 °C.
2.6. Mass spectrometry analysis
Unlabeled lipids of interest, re-extracted from silica plates were
analyzed by Electrospray Ionization Mass Spectrometry (ESI-MS). Total
lipid extracted from silica was dissolved in 100 μL of 1:1 (v/v) chlor-
oform:methanol containing 1mM LiCl. Prior to injection, samples were
diluted 1:10 and analyzed in the same solvent at an AmaZon SL Ion
Trap ESI Mass Spectrometer (Bruker) with injection rate of 3 μL/min in
positive and negative modes. The analysis was performed using the
following parameters: nitrogen gas nebulizers at 10 psi, drying gas at
5 L/min, source temperature at 200 °C, ionization source at 4.5 kV, and
collision gas with Helium. The analysis was carried out in the range of
50–900 m/z.
2.7. Alkaline hydrolysis
Purified lipid products, extracted from silica as described above,
were incubated with 200 μL of 100mM NaOH in 95% (v/v) aqueous
methanol or 100mM NaCl in 95% (v/v) aqueous methanol for 1 h at
37 °C. The treatment was terminated with 800 μL of 20% (v/v) acetic
acid and 200 μL 0.5M Tris-HCl pH 7.5. The products were desalted by
two extractions with 2 vol of butan-1-ol saturated with water followed
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by 1 vol water saturated with butan-1-ol. The samples were dried under
N2 gas and analyzed by HPTLC using running system 2.
2.8. Inositol uptake assay
For the uptake assay, promastigotes from exponential growth phase
(day 3 of culture) were washed three times in PBS pH 7.4 through
centrifugations at 3000×g for 10min at 4 °C, suspended at a density of
3× 108 promastigotes/mL in PBS and distributed in 100 μL aliquots
(3× 107 cells each). The uptake of the radiolabeled substrate was in-
itiated by the addition of 100 μL of the uptake solution consisting of
myo-inositol (50, 100, 200, 500, 1000 and 2000 μM) traced with 0.3 μCi
myo-[3H]-inositol (Inositol, myo-[2–3H(N)]-, specific activity 22.5 Ci/
mmol, PerkinElmer®, Boston, MA, USA) in PBS, pH 7.4] to the cell
suspension. At different times (between 1 and 60min), uptake was
stopped by adding 800 μL of cold stop solution (50mM unlabeled myo-
inositol in PBS, pH 7.4) and immediate transfer of samples to ice baths.
The parasite suspensions were washed three times in cold PBS (cen-
trifugation at 13,000×g for 50 s) to remove all free myo-[3H]-inositol.
Subsequently, cells were lysed in 100 μL of 1% SDS and the in-
corporated radioactivity was measured by liquid scintillation counting
(Beckman LS 5000 TD scintillation photometer). Radioactivity corre-
sponding to the experimental background was measured from parasites
that were simultaneously incubated with the uptake solution and stop
solution followed by the washing procedure and measurement analysis.
2.9. Effect of tamoxifen on inositol uptake
In order to evaluate the effect of tamoxifen on inositol uptake ac-
tivity in L. amazonensis promastigotes, cells were washed in PBS, and
then pre-incubated with 10, 30 and 50 μM tamoxifen for 10min at
25 °C. The uptake assays were conducted with increasing substrate
concentrations (50, 100, 200, 500, 1000 and 2000 μM myo-inositol plus
0.3 μCi myo-[3H]-inositol) during a fixed time of 2min. As inhibitor
control, 2 mM unlabeled myo- and scyllo-inositol were used at the Km
condition (200 μM myo-inositol plus 0.3 μCi myo-[3H]-inositol).
2.10. Inositol uptake data analysis
The incorporated radioactivity, expressed as counts per minute
(c.p.m.) of each experimental point was determined by subtracting the
average c.p.m. of background samples from the average c.p.m. of tri-
plicates after each time point. Curves were obtained from nonlinear
regressions to the expected exponential decay function (in the case of
time-course measurements) or hyperbolic function corresponding to
Michaelis-Menten equation (in the case of measurements of V0 as a
function of substrate concentrations). All data analysis and fittings were
performed with GraphPad Prism software 5. All data came from at least
three independent experiments performed with triplicate samples.
2.11. Cell viability
Parasite viability under the assay conditions was evaluated by
propidium iodide staining. Briefly, after the addition of stop solution,
an aliquot of parasites (10 μL) was removed, diluted 10 times in PBS
and incubated with 5 μg/mL propidium iodide for 5min at room tem-
perature. The propidium iodide fluorescence was observed by fluores-
cence microscopy under a 540 nm filter. The percentage of propidium
iodide positive cells was determined over the total cell count in a
Neubauer chamber.
2.12. IPC synthase assay
CHAPS-washed membranes containing Leishmania IPC synthase
were prepared and quantified from transgenic Saccharomyces cerevisiae
reliant on expression of the protozoan enzyme (α
ade−.lys−.leu−.Δaur1−.pESC-LEU_LmjFIPCS) as previously described
(Norcliffe et al., 2018), and 0.75U of enzyme used in a reaction mix
containing 100 μM PI (Avanti®Polar Lipids), 5 μM NBD-C6-ceramide
(ThermoFisher Scientific), 50mM PO4− pH7 and 600 μM CHAPS as
described previously (Mina et al., 2010, 2011) in the presence or ab-
sence of tamoxifen at the appropriate concentration in DMSO (0.8 μL).
Following incubation at 30 °C for 25min, the reaction product, NBD-C6-
IPC, was separated from the substrate, NBD-C6-ceramide, via anion
exchange chromatography on protonated AG4-X4 resin (Bio-Rad) in 96-
well MultiScreen® Solvinert filter plates (Merck Millipore), as pre-
viously described (Mina et al., 2010, 2011). After methanol washes,
NBD-C6-IPC was eluted from the resin in black OptiPlate-96 (Perki-
nElmer) plates using 1M potassium formate in methanol and quantified
using a Synergy HT microplate reader (Ex480/18; Em520/18) with the
Gen5™ version 2 package (Biotek). IC50 values were calculated using
sigmoidal regression analysis (GraphPad Prism7).
2.13. Statistical analysis
Data were analyzed for statistical significance by unpaired, two-
tailed T test calculated using GraphPad Prism 5 software.
3. Results
3.1. L. amazonensis promastigotes treated with tamoxifen displayed altered
sphingolipid biosynthesis
Metabolic labeling with [3H]-sphingosine or [3H]-inositol was em-
ployed to study the effect of tamoxifen on promastigotes' sphingolipid
metabolism. Total lipids were purified from control and treated para-
sites and analyzed by HPTLC. In extracts from control parasites labeled
with inositol, three well-defined bands were observed in the slower
migrating region. These products were named A, B and C (Fig. 1).
Metabolic labeling with sphingosine led to a more complex band pat-
tern including bands with the same retention factor (Rf) as bands A, B
and C. The detection of these 3 products after metabolic labeling with
the two precursors suggested that these lipids contained inositol and
sphingosine or sphingosine-derivatives in their composition. The pat-
tern observed after sphingosine labeling included other lipids migrating
with similar or higher Rfs. One of these, only slightly faster than lipid A
was named X (Fig. 1). One of the faster migrating and therefore less
polar molecules migrated with an Rf similar to the standard for C16
ceramide. Other labeled products were present, migrating with Rfs that
were not compatible with available standards. The fastest migrating
product among them (Rf=0.97), which was consistent with a nonpolar
molecule, was called band D (Fig. 1).
Parasites treated with 10 μM tamoxifen for 4 h exhibited differences
in the lipid profile compared to control extracts with a decrease in the
abundance of products migrating as bands A, B and C and an increase in
the abundance of lipid D (Fig. 1). The abundance of lipids A, B and C
from tamoxifen-treated and [3H]-inositol-labeled parasites was reduced
by 69 ± 14%, 77 ± 17% and 32 ± 13%, respectively, as compared
with the control untreated sample. In [3H]-sphingosine labeled cells,
the abundance of lipids B and C was 66 ± 19% and 68 ± 24% lower
in tamoxifen treated parasites in relation to control cells (Fig. Suppl. 1).
Quantification of lipid A after labeling with [3H]-sphingosine was not
performed due to the presence of another labeled lipid (X) migrating
with a similar Rf. The abundance of lipid D in treated parasites corre-
sponded to about twice (263 ± 62%) the signal in control parasites
(Fig. 1).
In summary, tamoxifen treated parasites decreased the abundance
of products presenting the same Rf when labeled with [3H]-sphingosine
(source for ceramide synthesis) or [3H]-inositol (source for the synthesis
of PI and IPC) (Fig. 1). Therefore, lipids A, B and C were potentially
molecules containing both sphingosine (or its derivatives) and inositol
in their structure.
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3.2. Characterization of lipids A and B
The nature of the products with altered biosynthesis in tamoxifen-
treated parasites was investigated through the analysis of the products
of their alkaline hydrolysis, by migration in different HPTLC running
systems and/or mass spectrometry.
Lipid B, derived from parasites labeled with [3H]-sphingosine and
eluted from the silica plate, showed resistance to alkaline hydrolysis
(Fig. 2), as expected for the IPC structure. Mass spectrometry (MS)
analysis of lipid B identified two predominant ions with m/z 778 and
806, previously described as IPC in L. major (Zhang et al., 2005; Hsu
et al., 2007) (Fig. 3A and B). The tandem mass spectrometry (MS2)
spectrum of m/z 778 indicated the presence of the following pre-
dominant ions: m/z 241 corresponding to cyclic inositol-1,2-phosphate,
m/z 259 corresponding to inositol monophosphate and m/z 223 that is
generated from 241 ions by the loss of water (Fig. 3C and D). These ions
are characteristic of IPC or PI molecules. The spectrum also showed ions
m/z 616 (m/z 778 − 162) and 598 (778 − 180) originated by inositol
dehydration and inositol loss, respectively (Hsu et al., 2007). Further-
more, there is the emergence of the ion m/z 512 (with weak strength)
which corresponds to the loss of a C18:0 acyl-bound fatty acid derived
ketone substituent (778 − 266). Similarly, the MS2 fragmentation of
the ion m/z 806 (Fig. 3E and F) showed characteristic ions of IPCs with
m/z 223, 241, 259, 644 (806 − 162) and 626 (806 − 180) and ion m/z
540 (weakly detected) which also corresponds to the loss of a C18:0
acyl-bound fatty acid derived ketone substituent (806 − 266). These
data suggest that the m/z 778 IPC is composed of d16:1/18:0 (Fig. 3G).
Similarly, MS2 fragmentation of the m/z 806 ion revealed a char-
acteristic IPC composed of d18:1/18:0 (Fig. 3H).
The analysis of lipid A by ESI-MS identified the prevalent ions m/z
598, 778, 796, 806 and 824 (Fig. 4A and B). The ion m/z 806 was
detected only in tamoxifen treated samples (Fig. 4A and B). Other peaks
detected did not match phospholipids containing inositol phosphate.
These ions can indicate the presence of possible glycerophospholipid
species (m/z 621, 653 and 671) that were not characterized further.
Based on the analysis of the MS2 spectra generated from each of
Fig. 1. Effect of tamoxifen treatment on L. amazonensis sphingolipid bio-
synthesis. Metabolic labeling of 1× 108 L. amazonensis promastigotes with
6 μCi of [3H]-sphingosine (lanes 2 and 3) or 6 μCi of [3H]-inositol (lanes 5 and
6). Parasites were treated with 10 μM tamoxifen for 4 h and purified total lipids
were analyzed by HPTLC using running system 1. ST(S): [3H]-sphingosine
standard without incubation with cells, ST(I): [3H]-inositol standard without
incubation with cells, Sph*: lipid extract of [3H]-sphingosine labeled parasites,
Ino*: lipid extract of [3H]-inositol labeled parasites, Ct: lipid extract of un-
treated parasites, Tam: lipid extract of parasites treated with tamoxifen, C16-
cer: C16-ceramide standard, PI 18:1: phosphatidylinositol 18:1 standard, O:
origin, F: front.
Fig. 2. Lipid B characterization by alkaline hydrolysis. Lipid B fractions
purified from HPTLC plates after separation of total lipids from L. amazonensis
promastigotes metabolic labeled with 2 μCi [3H]-sphingosine. Initial lipid ex-
tracts were obtained from parasites treated with 10 μM tamoxifen or left un-
treated. Eluted lipids were incubated in 100mM NaCl (lanes 1 and 2) or in
100mM NaOH (lanes 3 and 4) in 95% methanol aqueous solution for 1 h.
Extracts from 3×108 cells were applied to each lane and analyzed by HPTLC
using running system 2. Ct: lipid extract of untreated parasites, Tam: lipid ex-
tract of parasites treated with tamoxifen, NaCl: extract incubated with 100mM
NaCl, NaOH: extract incubated with 100mM NaOH, O: origin, F: front.
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these species (not shown), it was possible to identify the ion m/z 598 as
a C18:1 lyso-acyl PI (Pulfer and Murphy, 2003) (Fig. 4C). Although the
structure presented proposes the fatty acid bound to sn-1 of the glycerol
molecule (Fig. 4C), it is not possible to exclude a structure with a C18:1
fatty acid occupying the sn-2 position (Murphy and Axelsen, 2011). The
other ions detected corresponded to different IPCs composed of d16:1/
18:0-IPC (m/z 778, Fig. 4D), t16:0/C18:0-IPC (m/z 796, Fig. 4E),
d18:1/18:0-IPC (m/z 806, Fig. 4F) and t16:0/20:0-IPC (m/z 824,
Fig. 4G). The latter species have also been detected in small amounts in
ESI-MS analyses of IPCs isolated from of Leishmania major
promastigotes (Hsu et al., 2007).
Together, these data confirm that IPC was present in bands B and A
and suggested that tamoxifen decreased the biosynthesis of IPC in L.
amazonensis promastigotes.
3.3. Characterization of lipid C
Lipid C recovered from [3H]-sphingosine-labeled parasites was
sensitive to alkaline hydrolysis (data not shown) and migrated in run-
ning system 1 with Rfs compatible with an 18:1 PI standard (Fig. 1).
Fig. 3. ESI-MS analysis of lipid B. Lipid B fractions of L. amazonensis promastigotes untreated (A) or treated with 10 μM tamoxifen (B) were analyzed by ESI-MS in
the negative mode. MS2 spectra of ions m/z 778 and 806 (C/D and E/F, respectively) revealed characteristic ions of IPC molecules that were identified as IPC-(d16:1/
18:0) (G) and IPC-(d18:1/18:0) (H), respectively.
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Two other running systems were used to confirm the properties of lipid
C. Total lipid extracts of [3H]-sphingosine labeled L. amazonensis were
subjected to chromatography in two running systems previously used
for the study of PI (Castro et al., 2013; Martin and Smith, 2006) in
parallel with system 1, but with a longer run with the first solvent
(named as running system 2) to obtain better separation of bands in the
slower migration region (Fig. 5). In all three HPTLC analysis systems, a
labeled product migrating with the Rf of the 18: 1 PI standard was
observed (Fig. 5).
To confirm the molecular nature of lipid C, unlabeled products
migrating with the PI standard's Rf from a plate ran in the running
system 2, were scraped from the silica and analyzed by mass spectro-
metry (Fig. 6A and B). The analysis identified ions with m/z 835, 849
and 863, consistent with L. major PI ions described previously (Fig. 6A
and B) (Zhang et al., 2005; Hsu et al., 2007). The MS2 spectra of ion m/z
849 (Fig. 6C and D) demonstrated the presence of an ion with m/z 241
which, as observed on the analysis of the product identified as IPC (lipid
B), corresponded to the cyclic inositol-1,2-phosphate ion. Another
preponderant ion is the m/z 405, which corresponded to
[HPO4eCH]CHeCH2eOe(CH2)17eCH3]- (Serrano et al., 1995). Other
ions observed on the MS2 analysis included m/z 281, corresponding to
the carboxylated ion [CH3-(CH2)7eCH]CHe(CH2)7eCO2]- and prob-
ably arising from a C18:1 fatty chain originally acyl-bound to glycerol
sn-2 carbon. Finally, other two ions with m/z 585 and 567 were ob-
served and corresponded to C18:0 lyso-alkyl PI before and after losing
water (Pulfer and Murphy, 2003). These data suggested that the PI with
m/z 849 was composed by a sn-1-O-(C18:0) alkyl-2-O-(C18:1)acylgly-
cerol-3-HPO4-inositol (Fig. 6G). Similarly, the MS2 fragmentation of ion
m/z 863 (Fig. 6E and F) originated PI characteristic ions such as m/z
241 and 281. However, a high intensity ion at m/z 283 was also ap-
parent suggesting the presence of a carboxylated ion [CH3-
(CH2)16eCO2]- probably derived from a C18:0 fatty chain that was
originally acyl-linked to the sn-1 glycerol carbon. The m/z ∼296 ion
(296.879) is most likely the signal for glycerophosphoinositol – 2H2O.
Ions at m/z 437/419 and 599/581 were also noted, corresponding re-
spectively to C18:0 lyso-acyl phosphatidic acid and C18 lyso-acyl PI
before and after water loss (Pulfer and Murphy, 2003). These data
suggest that PI with m/z 863 is composed by sn-1-O-(C18:0)acyl-2-O-
Fig. 4. ESI-MS analysis of lipid A. Lipid A fractions of L. amazonensis promastigotes untreated (A) or treated with 10 μM tamoxifen (B) were analyzed by ESI-MS in
the negative mode. Ions m/z 598, 778, 796, 806 and 824 were identified as lyso-PI (18:1) (C), IPC (d16:1/18:0) (D), IPC (t16:0/18:0) (E), IPC (d18:1/18:0) (F) and
IPC (t16:0/20:0) (G), respectively.
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(C18:1)acylglycerol-3-HPO4-inositol (Fig. 6H). Therefore, lipid C, re-
duced in abundance in tamoxifen treated parasites was identified as PI.
3.4. Characterization of lipid D
Total lipids re-extracted from lipid D area were submitted to alka-
line hydrolysis and analyzed by HPTLC (Fig. 7). Prior to alkaline hy-
drolysis, extracts of tamoxifen-treated parasites presented an increased
abundance of lipid D in comparison to untreated parasites (Fig. 7, lanes
1 and 2). Lipid D migrated with an Rf similar to the acyl ceramide
standard. Upon alkaline treatment, a decrease in band D's intensity and
an increase in the abundance of a lipid with a retention profile similar
to the C16-ceramide standard was observed (Fig. 7, lane 4). Since al-
kaline hydrolysis characteristically results in the breakage of ester
bonds, this data suggested that lipid D is a ceramide with an additional
group, probably with non-polar features, that is linked to the molecule
by an ester bond. If we take into account the similar retention profile to
the standards, these results suggested that tamoxifen induced the in-
crease of acyl ceramide synthesis in L. amazonensis promastigotes.
3.5. Inositol availability in L. amazonensis promastigotes treated with
tamoxifen
Since the synthesis of IPC and PI depends on an intact pool of in-
ositol, we evaluated whether tamoxifen altered the activity of the in-
ositol transmembrane transporter in L. amazonensis promastigotes. An
initial evaluation of inositol uptake in these parasites was performed in
time-course incorporation curves during 60min in the presence of a
substrate concentration presumably close to the Km (0.5mM) ac-
cording to previous characterization of the myo-inositol transport and/
or uptake in L. donovani (Drew et al., 1995; Seyfang et al., 1997;
Seyfang and Landfear, 2000). A non-linear regression analysis showed
that data fitted to an exponential decay function (R2=0.9932) which,
as expected, is compatible with transporter facilitated uptake (Fig. Supl.
2A). The fact that the uptake was not saturated during the first 60min
strongly indicated that during this time the myo-inositol is metabolized
while it is transported into the cells. Additionally, the myo-inositol
uptake could be considered approximately linear during the first 10min
(R2= 0.9980) (Inset, Fig Supl. 2A), allowing us to calculate V0 inside
this range of time (Fig. Supl. 2A). From this analysis, we chose to cal-
culate V0 based on the substrate uptake during 2min of incubation of
the parasites with myo-inositol.
The substrate saturation curve with substrate concentrations ran-
ging from 0.05 to 2mM inositol exhibited a classical Michaelis-Menten
kinetics with values of Km and Vmax of 163.5 (131.8–195.1) μM and
62.5 (58.9–66.0) pmol min−1 3×107 cells−1 (mean ± 95% con-
fidence interval), respectively (Fig Supl. 2B).
Under the hypothesis that inositol uptake by L. amazonensis pro-
mastigotes could be diminished by tamoxifen, this process was eval-
uated at substrate concentrations equivalent to the Km (0.2 mM myo-
[3H]-inositol) and to concentrations allowing Vmax transport (2 mM
myo-[3H]-inositol) in parasites previously incubated with 10, 30 and
50 μM tamoxifen for 10min (Fig. 8A). In all treated samples, the
number and viability of parasites were preserved as compared to the
untreated group (Table 1), showing that the reduction on inositol up-
take observed in parasites treated with tamoxifen was not due to
parasites' death. Tamoxifen induced a dose-dependent decrease on in-
ositol incorporation in L. amazonensis promastigotes (Fig. 8A). When
assayed at the Km conditions, parasites treated with 10, 30 and 50 μM
tamoxifen showed 11%, 21% and 41% reductions on myo-[3H]-inositol
uptake, respectively. When assayed at Vmax conditions, inositol in-
corporation was decreased by 10.9%, 11.8% and 33.1%, respectively.
As a control for these drug inhibition assays, 2 mM of myo- and scyllo-
inositol were used as competitive inhibitors. When assayed at Km
conditions, myo- and scyllo-inositol inhibited inositol uptake by 81%
and 84%, respectively (Fig. 8A). Such inhibition was greater than that
observed in parasites treated with the highest dose of tamoxifen.
Substrate saturation curves were calculated from parasites treated
with 0, 10, 30 and 50 μM tamoxifen, allowing the determination of the
Km and Vmax for each condition (Fig. 8B, Table 2). Assuming that the
myo-inositol transporter can be a target for tamoxifen, the observed
changes on Vmax values in the presence of tamoxifen are compatible
with a non-competitive inhibition is taking place, with tamoxifen
binding at a distinct site from the substrate active site. The double-
reciprocal plot (Inset, Fig. 8B) constructed from the obtained saturation
curve supported this possibility.
Therefore, while 10 μM tamoxifen led to clear disturbances on lipid
metabolism, its effect was only mild on inositol uptake, suggesting that
the latter may not be the relevant target. Notwithstanding, to verify
whether inositol availability had an impact on PI and IPC biosynthesis
in tamoxifen-treated cells, a metabolic labeling assay was performed to
evaluate PI and IPC synthesis in the presence of high concentrations of
inositol. Metabolic labeling of L. amazonensis promastigotes previously
treated with 10 μM tamoxifen was performed with [3H]-sphingosine or
[3H]-inositol in the absence or in the presence of 0.2 or 2mM unlabeled
inositol (Fig. 9). In parasites labeled with [3H]-inositol (Fig. 9, lines 1 to
6), the presence of increasing concentrations of unlabeled inositol led to
a gradual reduction on label incorporation on PI (Lipid C) and IPC
(Lipids A and B) (Fig. 9). This effect occurred in both control and
treated samples, and is probably related to the dilution of the radio-
active labeling. However, tamoxifen-treated parasites metabolically
labeled with [3H]-sphingosine presented reduced PI and IPC synthesis
despite the increased concentrations of unlabeled inositol. These data
confirmed that the reduced synthesis of PI and IPC in parasites treated
with tamoxifen is not due to the lack of inositol availability to the cells.
3.6. Effect of tamoxifen on the Leishmania IPC synthase
Since the availability of inositol did not explain the reduced bio-
synthesis of PI and IPC in tamoxifen treated promastigotes, we in-
vestigated whether tamoxifen was an IPC synthase inhibitor.
Tamoxifen's effect on Leishmania IPC synthase was investigated using
the fluorescent based cell-free assay of L. major IPC synthase developed
Fig. 5. Separation of total lipid extracts from L. amazonensis promastigotes
in different HPTLC systems. Parasites (7× 108 L. amazonensis promastigotes)
were metabolic labeled with 2 μCi [3H]-sphingosine. Total lipid extract corre-
sponding to 1× 108 cells was added to each lane and separated by HPTLC using
running systems 2 (A), 3 (B) and 4 (C). Sph*: [3H]-sphingosine standard, 18:1
PI: 18:1 phosphatidylinositol standard, O: origin, F: front.
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by Mina and co-workers (Mina et al., 2010). In this system, the drug is
incubated with C6-NBD-ceramide (receiving substrate) and PI (donor
substrate) in the presence of CHAPS washed S. cerevisiae microsomal
extracts containing the L. major IPC synthase. Tamoxifen inhibited L.
major IPC synthase with an IC50 value of 8.48 μM (95% CI 7.68–9.37)
(Fig. 10).
4. Discussion
Current therapeutic options for leishmaniasis are of limited efficacy
and safety and new alternatives are clearly needed. Due the promising
therapeutic profile observed for tamoxifen in different animal models of
leishmaniasis, we undertook to evaluate its mechanism of action
against the parasite. [3H]-sphingosine and myo-[3H]-inositol metabolic
labeling of L. amazonensis promastigotes treated with tamoxifen showed
a meaningful perturbation of SL metabolism, leading to a significant
reduction of IPCs and PIs, and accumulation of acyl ceramide.
IPC, the most abundant SL in Leishmania, is present in lipid rafts
(Kaneshiro et al., 1986; McConville and Bacic, 1989; Yoneyama et al.,
2006) that are involved in cell signaling and macrophage invasion as
well as in the process of promastigote migration in the vector's gut
during metacyclogenesis (Denny and Smith, 2004; Denny et al., 2004;
Yoneyama et al., 2006). IPC is essential for fungi and for the blood-
stream forms of Trypanosoma brucei (Nagiec et al., 1997; Sutterwala
et al., 2008; Mina et al., 2009).
PI is an essential phospholipid in eukaryotes that, together with its
Fig. 6. ESI-MS analysis of lipid C. Lipid C fractions of L. amazonensis promastigotes untreated (A) or treated with 10 μM tamoxifen (B) were analyzed by ESI-MS in
the negative mode. MS2 spectra of ions m/z 849 and 863 (C/D and E/F, respectively) revealed characteristic ions of PI molecules that were identified as PI-(O-18:0/
18:1) (G) and PI-(18:0/18:1) (H), respectively.
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metabolites, regulate a wide range of cellular processes. In addition, it
is a substrate for PI kinases (PIKs), key enzymes of one of the major
intracellular signaling pathways of eukaryotic cells (reviewed in Martin
and Smith, 2006; Sasaki et al., 2009). This pathway consists in one of
the main targets for cancer chemotherapy and may represent a very
interesting focus for the treatment of parasitic diseases (Braga and de
Souza, 2006; Fernandes et al., 2006). PI3k3 has been shown to mediate
invasion of macrophages and neutrophils by L. mexicana in vitro and the
recruitment of phagocytes and regulatory T cells into the site of infec-
tion in in vivo studies (Cummings et al., 2012; Oghumu and Satoskar,
2013). Consequently, the reduction of IPC and PI synthesis in L. ama-
zonensis promastigotes treated with tamoxifen may have important re-
percussions in the establishment of Leishmania infection, as well as cell
viability. Two hypotheses were formulated to explain the reduction of
PI and IPC abundance in tamoxifen's treated parasites: (1) tamoxifen
interferes in inositol and/or ceramide availability, both being critical
elements for IPC synthesis; (2) tamoxifen inhibits IPC and/or PI syn-
thase (Fig. 11).
In Leishmania, inositol can be acquired by de novo synthesis or up-
take through specific membrane transporters (Drew et al., 1995; Ilg,
2002; Majumder et al., 1997; Michell, 2008; Reynolds, 2009). Inositol
de novo synthesis occurs in the cell cytoplasm by cytosolic enzymes
(Donahue and Henry, 1981; Michell, 2008), which are unlikely to be a
target for tamoxifen, a lipophilic molecule (Log P=5.93) that is known
to interact and incorporate into biomembranes (Custodio et al., 1998).
A myo-inositol transporter has been described in L. donovani (Drew
et al., 1995). A single copy gene encodes this protein, which behaves as
a myo-inositol/proton electrogenic symporter (Drew et al., 1995;
Seyfang et al., 1997). Regulation of inositol uptake activity has been
correlated with the availability of substrate with upregulated expres-
sion and activity when the substrate is depleted from the external
environment (Seyfang and Landfear, 1999). The myo-inositol trans-
porter, localized in the plasma membrane of L. donovani promastigotes,
was shown to be redirected to the multivesicular tubule in stationary
phase promastigotes and to the lysosome following transformation to
the intracellular amastigote form (Vince et al., 2011), suggesting that
transport activity is more important during the insect stage. The
transport kinetics of the L. amazonensis myo-inositol transporter char-
acterized here were similar to the ones described previously for L. do-
novani (Km 250 ± 0.05 μM and Vmax: 55,5 ± 8.8 pmol min−1 5× 107
células−1) (Drew et al., 1995).
The characterization of inositol uptake in tamoxifen-treated para-
sites indicated the occurrence of a non-competitive inhibition (Fig. 8),
suggesting that tamoxifen does not bind at the substrate active site. It is
important to stress that even in the presence of 50 μM tamoxifen
(equivalent to 5x the IC50) the maximal uptake inhibition observed was
40%. Considering that the metabolic labeling of parasites was per-
formed after treatment with 10 μM tamoxifen (for longer periods), it
seemed unlikely that inhibition of inositol transport was the sole reason
for reduced synthesis of IPC and PI.
The confirmation that inositol availability had no impact on PI and
IPC biosynthesis was validated by metabolic labeling of parasites with
[3H]-sphingosine or [3H]-inositol in presence of high concentrations of
unlabeled inositol (Fig. 9).
The reduction of PI and IPC synthesis in tamoxifen-treated parasites
despite the increased concentrations of unlabeled inositol suggested
that the enzymes IPC and/or PI synthase could be targets of the drug. A
well-established cell-free assay of L. major IPC synthase was used to
demonstrate the inhibitory activity of tamoxifen on Leishmania IPC
synthase with an IC50 in the lower micromolar range [IC50= 8.48 μM
(95% CI 7.68–9.37)] (Fig. 10). Under IPC synthase inhibition, an in-
crease in PI concentration could be expected but is not observed,
Fig. 7. Lipid D characterization by alkaline hydrolysis.
(A) Acyl ceramide structure. (B) Total lipid extracts from
lipid D fractions of [3H]-sphingosine metabolic labeled L.
amazonensis promastigotes treated or not with 10 μM ta-
moxifen were incubated in 100mM NaOH (lane 3 and 4) or
NaCl (lane 1 and 2) in 95% methanol aqueous solution for
1 h. Total lipid extracts from 3×108 cells were applied to
each lane and analyzed by HPTLC using running system 2. D:
lipid D, Acyl-cer: Acyl-ceramide standard, C16-cer: C16-cer-
amide standard, Ct: lipid extract of untreated parasites, Tam:
lipid extract of parasites treated with tamoxifen, NaCl: ex-
tract incubated with 100mM NaCl, NaOH: extract incubated
with 100mM NaOH, O: origin, F: front.
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suggesting that PI synthesis may also be impaired. However, a possible
direct drug inhibition of PI synthase activity was not shown here and
still needs to be investigated.
Both PI and IPC synthase, as well as other enzymes involved in the
SLs biosynthesis, are transmembrane proteins with several transmem-
brane domains (Martin and Smith, 2006; Sutterwala et al., 2008). Since
tamoxifen in known to interact with the cell membrane, it is possible
that, in doing so, it could promote an alteration in the three-dimen-
sional structure of IPC/PI synthase resulting in impairment of enzy-
matic activity. Aside from its proposed inhibitory effect on PI and IPC
synthases, tamoxifen could also interfere with other enzymes of the
metabolism of sphingolipids in Leishmania like the phosphorylation of
sphingosine to form S1P and its degradation by S1PL that give rise to
hexadecenal (that can be used to the biosynthesis of glyceropho-
spholipids) and ethanolamine-phosphate (that can be used to the bio-
synthesis of phosphatidylethanolamine) (Nakahara et al., 2012). The
Fig. 8. Interference of tamoxifen on inositol uptake of L. amazonensis
promastigotes. (A) Effect of tamoxifen (10, 30, and 50 μM) on myo-inositol
uptake at Km (200 μM myo-inositol plus 0.3 μCi myo-[3H]-inositol) and Vmax
(2000 μM myo-inositol plus 0.3 μCi myo-[3H]-inositol) conditions. Unlabeled
2mM myo- and scyllo-inositol were used as inhibitors at the Km condition. (B)
myo-inositol uptake kinetics in L. amazonensis promastigotes treated with dif-
ferent concentrations of tamoxifen. Inset: Double reciprocal plot of the linear
inhibition of inositol uptake at the different concentrations of tamoxifen com-
pared to untreated control. The uptake assays were conducted with increasing
substrate concentrations (50, 100, 200, 500, 1000 and 2000 μM myo-inositol
plus 0.3 μCi myo-[3H]-inositol) during a fixed time of 2 min. Results are re-
presentative of three experiments performed in each case. The bars represent
the standard deviation of duplicates or triplicates. The myo-inositol in-
corporations is shown as picomoles per minute per 3× 107 promastigotes.
Table 1
Cell concentration and viability of L. amazonensis promastigotes treated with
different tamoxifen concentrations for 10min at 25 °C.
Tamoxifen (μM) Promastigotes (cells/mL) Cell viability (%)a
0 2.0× 107 91
10 2.0× 107 91
30 2.2× 107 95
50 2.1× 107 93
a Percentage of propidium iodide unlabeled cells.
Table 2
L. amazonensis inositol transporter Km and Vmax after treatment with tamoxifen for 10min at 25 °C.
Tamoxifen (μM) Kma [μM (CI95%)] Vmaxb [pmol min−1 3×107 cells−1(CI95%)]
0 182.9 (155.0–210.9) 76.5 (72.9–80.2)
10 193.9 (137.2–250.6) 66.8 (60.8–72.7)
30 203.2 (146.4–260.0) 63.7 (58.0–69.4)
50 197.7 (141.1–254.4) 50.9 (46.6–55.2)
a Michaelis-Menten constant expressed in micromolar and 95% confidence interval.
b Maximum velocity of inositol uptake expressed in picomoles per minute per 3× 107 cells and 95% confidence interval.
Fig. 9. Sphingolipid biosynthesis in L. amazonensis promastigotes treated
with tamoxifen. L. amazonensis promastigotes (4×108) were treated with
tamoxifen and metabolic labeled with 6 μCi [3H]-inositol (1–6) or 2 μCi [3H]-
sphingosine (7–10). Parasites were supplemented with 0.2 (2, 5, 9) or 2 mM (3,
6, 10) myo-inositol. Total lipid extracts from 1×108 cells were spotted on each
lane and analyzed by HPTLC using running system 1. Tam: 10 μM tamoxifen for
4 h; Sph*: labeling with [3H]-sphingosine; Ino*: labeling with [3H]-inositol; Ino:
unlabeled inositol; O: origin; F: front.
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latter product could not be traced in our metabolic labelling experi-
ments using [3H]-sphingosine, once the [3H] was located at the
sphingosine C-2. On the other hand, the resulting hexadecenal would be
labeled and could be incorporated into PI molecules (more specifically
to the PI with m/z 849), a process that was apparently inhibited by
tamoxifen (Fig. 1). In this pathway, the labeled hexadecenal is used as a
substrate for the alkyl-dihydroxyacetone phosphate (DHAP) synthase to
generate alkyl-DHAP which will subsequently be reduced into alkyl-
glycerol-3-phosphate that can be used in the biosynthesis of ether gly-
cerophospholipids.
The mass spectrometry analysis also disclosed the presence of some
other lipid species (m/z 621, 653, 671 and 806) that were not char-
acterized but may be of interest to better understand the biochemistry
of tamoxifen activity over these lipids in Leishmania.
The deletion of the IPC synthase gene in S. cerevisiae leads to ac-
cumulation of intracellular ceramide followed by cell death (Nagiec
et al., 1997). In addition, several studies have indicated the accumu-
lation of intracellular ceramide in tumor cells submitted to treatment
with tamoxifen (Morad et al., 2013; Morad and Cabot, 2015). The anti-
proliferative and cell death triggering effects of high intracellular
concentrations of ceramide are well characterized in eukaryotic cells
(Jayadev et al., 1995; Wang et al., 2003; Chapman et al., 2010;
Tirodkar and Voelkel-Johnson, 2012). Instead, the increase of sphin-
gosine and sphingosine-1-phosphate is related to cell survival and
proliferation (Smith et al., 2000; Rodriguez et al., 2015). The balance
between these and other active SLs and enzymes of SL metabolism plays
a very important role in the pathogenesis and progression of cancer in
humans (Ogretmen and Hannun, 2004).
Tamoxifen has been shown to inhibit the activity of acid cer-
amidases in human tumoral cells (Morad et al., 2013; Morad and Cabot,
2015), resulting in accumulation of ceramide. An increase in ceramide
levels was not observed in tamoxifen-treated parasites (Fig. 1). On the
other hand, the present data show an increased synthesis of acylated
ceramide in L. amazonensis promastigotes treated with tamoxifen. Acyl-
ceramide is an uncommon form of ceramide not yet described in
Leishmania spp. In humans, 1-O-acylceramide has been identified as a
natural component of the human and murine epidermis, which con-
tributes to the homeostasis of the skin hydration barrier (Rabionet
et al., 2013). Since intracellular ceramide level is tightly regulated in
eukaryotic cells, the ceramide acylation could occur as a protective
mechanism.
Considering that tamoxifen-treated parasites showed a reduction of
IPC (lipid A and B), the most abundant membrane phosphosphingolipid
in Leishmania, it is reasonable to assume that inhibition of IPC synthase
could result in accumulation of intracellular ceramide. The similar in-
tensity of the product with comparable Rf to C16-ceramide pattern in
[3H]-sphingosine-labeled parasites treated or not with tamoxifen
(Figs. 1 and 7), even though in conditions of IPC synthase inhibition,
supports the hypothesis that intracellular ceramides were acylated to
maintain ceramide physiological levels and cell homeostasis.
In summary, we have shown that tamoxifen alters the profile of
incorporation of [3H]-sphingosine and [3H]-inositol precursors in the
sphingolipid biosynthesis pathway in L. amazonensis promastigotes,
leading to the reduction of PI and IPC synthesis, with accumulation of
acylated ceramide. The reduction in IPC, with the corollary increase in
ceramide, seen in Leishmania treated with tamoxifen, coupled with the
inhibitory action on parasite IPC synthase activity in vitro, indicated
that inhibition of IPC synthesis may represent a key leishmanicidal
mechanism of action of this drug. IPC synthase is a very interesting
target since it represents an essential enzyme responsible for the
synthesis of the most abundant SL in Leishmania (Kaneshiro et al., 1986;
McConville and Bacic, 1989) which is absent in mammals (Denny et al.,
2004). Recent work has seen a yeast-based assay employed to discover
new, selective inhibitors with activity against intramacrophage Leish-
mania (Norcliffe et al., 2018). In addition, we have shown that ta-
moxifen treatment leads to the reduction of PI abundance, which could
have a wide range of effects on cellular function, since numerous
Fig. 10. Effect of tamoxifen on the turnover of Leishmania IPC synthase.
IC50 of tamoxifen (2-fold serial dilution from 200 μM top concentration) against
the L. major IPC synthase in the in vitro assay was calculated using GraphPad
Prism 7 (log (inhibitor) vs. normalized response - Variable slope) as 8.48 μM
(95% CI 7.68–9.37). Seven replicate data set, error bars represent standard
deviation (not visible where very small), and R2=0.98.
Fig. 11. Schematic diagram summarizing potential ta-
moxifen targets related to sphingolipid biosynthesis in
Leishmania. Reduced IPC levels (blue arrows) in L. amazo-
nensis promastigotes treated with tamoxifen are related to
IPC synthase inhibition (red bars). Reduced PI and IPC in-
tracellular levels (blue arrows) could also be related to re-
duced incorporation of inositol into the cell or to direct or
indirect inhibition of PI and/or IPC synthase (purple bars).
The increased levels of acylated ceramide may be a result
from intracellular ceramide accumulation (green arrow) due
to its reduced use as a source for IPC synthesis. Labeled PI
observed in [3H]-Sphingosine-labeled parasites may be gen-
erated by hexadecenal pathway from sphingosine-1-phos-
phate degradation. DAG: diacylglycerol; CDP-DAG: cytidine
diphosphate diacylglycerol; PIS: phosphatidylinositol syn-
thase; IPC: inositolphophorylceramide; EtN-P: phosphoeta-
lonamine; Alkyl-G3P: 1-alkylglycerol-3-phosphate; CDase:
ceramidase; CDP-DAG: cytidine diphosphate diacylglycerol;
CerS: ceramide synthase; DAG: diacylglycerol; EtN-P: phos-
phoetalonamine; IPC: inositolphophorylceramide; IPCS: in-
ositolphosphorylceramide synthase; ISCL: inositol-
sphingolipid phospholipase C-like; PI: phosphatidylinositol; PIS: phosphatidylinositol synthase; S1PL: sphingosine-1-phosphate lyase; Sph-1-P: sphingosine-1-
phosphate; TAM: tamoxifen. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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biological functions of PI are known in eukaryotic cells (Divecha and
Irvine, 1995; Henry and Patton-Vogt, 1998; Odom et al., 2000; Martin,
2001; Sasaki et al., 2009).
We have shown previously that methods normally used to select
parasites resistant to drugs failed when tamoxifen resistance is pursued
(Coelho et al., 2015), making it likely that several targets in the cell are
capable of justifying tamoxifen's leishmanicidal effect, just as it occurs
in human tumor cells.
5. Conclusions
Promastigotes of L. amazonensis treated with tamoxifen presented
reduced IPC and PI biosynthesis. The reduction in IPC biosynthesis
cannot be attributed to reduction in inositol transport but is probably
related to inhibition of the IPC synthase.
Funding
This work was supported by grant 2015/09080-2, São Paulo
Research Foundation (FAPESP), grant 473343/2012-6, Conselho
Nacional de Desenvolvimento Científico e Tecnológico (CNPq),
Coordenacão de Aperfeiçoamento de Pessoal de Nível Superior
(CAPES), and the research leading to these results has, in part, received
funding from the Research Councils UK Grand Challenges Research
Funder under grant agreement ‘A Global Network for Neglected
Tropical Diseases’ grant number MR/P027989/1. C. T. T. (2011/18858-
6) was supported by a FAPESP fellowship. S. R. B. U. is the recipient of a
senior researcher scholarship from CNPq.
Acknowledgments
We thank Alejandro Katzin for contributing with discussions and
equipment availability. We would also like to thank Caroline Ricce
Espada, Victor de Sousa Agostino, Mariana K. Galuppo e Jenicer K. U.
Yokoyama-Yasunaka for support and helpful discussions.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ijpddr.2018.10.007.
References
Alvar, J., Croft, S., Olliaro, P., 2006. Chemotherapy in the treatment and control of
leishmaniasis. Adv. Parasitol. 61, 223–274.
Alvar, J., Velez, I.D., Bern, C., Herrero, M., Desjeux, P., Cano, J., Jannin, J., den Boer, M.,
2012. Leishmaniasis worldwide and global estimates of its incidence. PloS One 7,
e35671.
Boath, A., Graf, C., Lidome, E., Ullrich, T., Nussbaumer, P., Bornancin, F., 2008.
Regulation and traffic of ceramide 1-phosphate produced by ceramide kinase: com-
parative analysis to glucosylceramide and sphingomyelin. J. Biol. Chem. 283,
8517–8526.
Braga, M.V., de Souza, W., 2006. Effects of protein kinase and phosphatidylinositol-3
kinase inhibitors on growth and ultrastructure of Trypanosoma cruzi. FEMS Microbiol.
Lett. 256, 209–216.
Cabot, M.C., Giuliano, A.E., Volner, A., Han, T.Y., 1996. Tamoxifen retards glyco-
sphingolipid metabolism in human cancer cells. FEBS Lett. 394, 129–131.
Castro, E.V., Yoneyama, K.G., Haapalainen, E.F., Toledo, M.S., Takahashi, H.K., Straus,
A.H., 2013. Myriocin, a serine palmitoyltransferase inhibitor, blocks cytokinesis in
Leishmania (Viannia) braziliensis promastigotes. J. Eukaryot. Microbiol. 60, 377–387.
Chapman, J.V., Gouaze-Andersson, V., Messner, M.C., Flowers, M., Karimi, R., Kester, M.,
Barth, B.M., Liu, X., Liu, Y.Y., Giuliano, A.E., Cabot, M.C., 2010. Metabolism of short-
chain ceramide by human cancer cells–implications for therapeutic approaches.
Biochem. Pharmacol. 80, 308–315.
Charlton, R., Rossi-Bergmann, B., Denny, P., Steel, P., 2018. Repurposing as a strategy for
the discovery of new anti-leishmanials: the-state-of-the-art. Parasitology 145,
219–236.
Coelho, A.C., Trinconi, C.T., Senra, L., Yokoyama-Yasunaka, J.K., Uliana, S.R., 2015.
Leishmania is not prone to develop resistance to tamoxifen. Int. J. Parasitol. Drugs
Drug Resist. 5, 77–83.
Convit, J., Ulrich, M., 1993. Antigen-specific immunodeficiency and its relation to the
spectrum of american cutaneous leishmaniasis. Biol. Res. 26, 159–166.
Croft, S.L., Coombs, G.H., 2003. Leishmaniasis- current chemotherapy and recent ad-
vances in the search for novel drugs. Trends Parasitol. 19, 502–508.
Cummings, H.E., Barbi, J., Reville, P., Oghumu, S., Zorko, N., Sarkar, A., Keiser, T.L., Lu,
B., Ruckle, T., Varikuti, S., Lezama-Davila, C., Wewers, M.D., Whitacre, C., Radzioch,
D., Rommel, C., Seveau, S., Satoskar, A.R., 2012. Critical role for phosphoinositide 3-
kinase gamma in parasite invasion and disease progression of cutaneous leishma-
niasis. Proc. Natl. Acad. Sci. U. S. A. 109, 1251–1256.
Custodio, J.B., Moreno, A.J., Wallace, K.B., 1998. Tamoxifen inhibits induction of the
mitochondrial permeability transition by Ca2+ and inorganic phosphate. Toxicol.
Appl. Pharmacol. 152, 10–17.
Denny, P.W., Smith, D.F., 2004. Rafts and sphingolipid biosynthesis in the kinetoplastid
parasitic protozoa. Mol. Microbiol. 53, 725–733.
Denny, P.W., Goulding, D., Ferguson, M.A., Smith, D.F., 2004. Sphingolipid-free
Leishmania are defective in membrane trafficking, differentiation and infectivity. Mol.
Microbiol. 52, 313–327.
Denny, P.W., Shams-Eldin, H., Price, H.P., Smith, D.F., Schwarz, R.T., 2006. The proto-
zoan inositol phosphorylceramide synthase: a novel drug target that defines a new
class of sphingolipid synthase. J. Biol. Chem. 281, 28200–28209.
Divecha, N., Irvine, R.F., 1995. Phospholipid signaling. Cell 80, 269–278.
Donahue, T.F., Henry, S.A., 1981. myo-Inositol-1-phosphate synthase. Characteristics of
the enzyme and identification of its structural gene in yeast. J. Biol. Chem. 256,
7077–7085.
Drew, M.E., Langford, C.K., Klamo, E.M., Russell, D.G., Kavanaugh, M.P., Landfear, S.M.,
1995. Functional expression of a myo-inositol/H+ symporter from Leishmania dono-
vani. Mol. Cell Biol. 15, 5508–5515.
Fernandes, A.B., Neira, I., Ferreira, A.T., Mortara, R.A., 2006. Cell invasion by
Trypanosoma cruzi amastigotes of distinct infectivities: studies on signaling pathways.
Parasitol. Res. 100, 59–68.
Figueiredo, J.M., Dias, W.B., Mendonca-Previato, L., Previato, J.O., Heise, N., 2005.
Characterization of the inositol phosphorylceramide synthase activity from
Trypanosoma cruzi. Biochem. J. 387, 519–529.
Henry, S.A., Patton-Vogt, J.L., 1998. Genetic regulation of phospholipid metabolism:
yeast as a model eukaryote. Prog. Nucleic Acid Res. Mol. Biol. 61, 133–179.
Hsu, F.F., Turk, J., Zhang, K., Beverley, S.M., 2007. Characterization of inositol phos-
phorylceramides from Leishmania major by tandem mass spectrometry with electro-
spray ionization. J. Am. Soc. Mass Spectrom. 18, 1591–1604.
Ichikawa, S., Nakajo, N., Sakiyama, H., Hirabayashi, Y., 1994. A mouse B16 melanoma
mutant deficient in glycolipids. Proc. Natl. Acad. Sci. U. S. A. 91, 2703–2707.
Ilg, T., 2002. Generation of myo-inositol-auxotrophic Leishmania mexicana mutants by
targeted replacement of the myo-inositol-1-phosphate synthase gene. Mol. Biochem.
Parasitol. 120, 151–156.
Jayadev, S., Liu, B., Bielawska, A.E., Lee, J.Y., Nazaire, F., Pushkareva, M., Obeid, L.M.,
Hannun, Y.A., 1995. Role for ceramide in cell cycle arrest. J. Biol. Chem. 270,
2047–2052.
Jordan, V.C., 2003. Tamoxifen: a most unlikely pioneering medicine. Nat. Rev. Drug
Discov. 2, 205–213.
Kaneshiro, E.S., Jayasimhulu, K., Lester, R.L., 1986. Characterization of inositol lipids
from Leishmania donovani promastigotes: identification of an inositol sphingopho-
spholipid. J. Lipid Res. 27, 1294–1303.
Majumder, A.L., Johnson, M.D., Henry, S.A., 1997. 1L-myo-inositol-1-phosphate synthase.
Biochim. Biophys. Acta 1348, 245–256.
Martin, K.L., Smith, T.K., 2006. Phosphatidylinositol synthesis is essential in bloodstream
form Trypanosoma brucei. Biochem. J. 396, 287–295.
Martin, T.F., 2001. PI(4,5)P(2) regulation of surface membrane traffic. Curr. Opin. Cell
Biol. 13, 493–499.
McConville, M.J., Bacic, A., 1989. A family of glycoinositol phospholipids from
Leishmania major. Isolation, characterization, and antigenicity. J. Biol. Chem. 264,
757–766.
Merrill Jr., A.H., 2011. Sphingolipid and glycosphingolipid metabolic pathways in the era
of sphingolipidomics. Chem. Rev. 111, 6387–6422.
Michell, R.H., 2008. Inositol derivatives: evolution and functions. Nat. Rev. Mol. Cell Biol.
9, 151–161.
Miguel, D.C., Yokoyama-Yasunaka, J.K., Andreoli, W.K., Mortara, R.A., Uliana, S.R.,
2007. Tamoxifen is effective against Leishmania and induces a rapid alkalinization of
parasitophorous vacuoles harbouring Leishmania (Leishmania) amazonensis amasti-
gotes. J. Antimicrob. Chemother. 60, 526–534.
Miguel, D.C., Yokoyama-Yasunaka, J.K., Uliana, S.R., 2008. Tamoxifen is effective in the
treatment of Leishmania amazonensis infections in mice. PLoS Neglected Trop. Dis. 2,
e249.
Miguel, D.C., Zauli-Nascimento, R.C., Yokoyama-Yasunaka, J.K., Katz, S., Barbieri, C.L.,
Uliana, S.R., 2009. Tamoxifen as a potential antileishmanial agent: efficacy in the
treatment of Leishmania braziliensis and Leishmania chagasi infections. J. Antimicrob.
Chemother. 63, 365–368.
Mina, J., Denny, P., 2018. Everybody needs sphingolipids, right! Mining for new drug
targets in protozoan sphingolipid biosynthesis. Parasitology 145, 134–147.
Mina, J.G., Mosely, J.A., Ali, H.Z., Denny, P.W., Steel, P.G., 2011. Exploring Leishmania
major inositol phosphorylceramide synthase (LmjIPCS): insights into the ceramide
binding domain. Org. Biomol. Chem. 9, 1823–1830.
Mina, J.G., Mosely, J.A., Ali, H.Z., Shams-Eldin, H., Schwarz, R.T., Steel, P.G., Denny,
P.W., 2010. A plate-based assay system for analyses and screening of the Leishmania
major inositol phosphorylceramide synthase. Int. J. Biochem. Cell Biol. 42,
1553–1561.
Mina, J.G., Pan, S.Y., Wansadhipathi, N.K., Bruce, C.R., Shams-Eldin, H., Schwarz, R.T.,
Steel, P.G., Denny, P.W., 2009. The Trypanosoma brucei sphingolipid synthase, an
essential enzyme and drug target. Mol. Biochem. Parasitol. 168, 16–23.
Morad, S.A., Cabot, M.C., 2015. Tamoxifen regulation of sphingolipid metabolism–
C.T. Trinconi et al. IJP: Drugs and Drug Resistance 8 (2018) 475–487
486
Therapeutic implications. Biochim. Biophys. Acta 1851, 1134–1145.
Morad, S.A., Levin, J.C., Tan, S.F., Fox, T.E., Feith, D.J., Cabot, M.C., 2013. Novel off-
target effect of tamoxifen–inhibition of acid ceramidase activity in cancer cells.
Biochim. Biophys. Acta 1831, 1657–1664.
Murphy, R.C., Axelsen, P.H., 2011. Mass spectrometric analysis of long-chain lipids. Mass
Spectrom. Rev. 30, 579–599.
Nagiec, M.M., Nagiec, E.E., Baltisberger, J.A., Wells, G.B., Lester, R.L., Dickson, R.C.,
1997. Sphingolipid synthesis as a target for antifungal drugs. Complementation of the
inositol phosphorylceramide synthase defect in a mutant strain of Saccharomyces
cerevisiae by the AUR1 gene. J. Biol. Chem. 272, 9809–9817.
Nakahara, K., Ohkuni, A., Kitamura, T., Abe, K., Naganuma, T., Ohno, Y., Zoeller, R.A.,
Kihara, A., 2012. The Sjogren-Larsson syndrome gene encodes a hexadecenal dehy-
drogenase of the sphingosine 1-phosphate degradation pathway. Mol. Cell. 46,
461–471.
Norcliffe, J.L., Mina, J.G., Alvarez, E., Cantizani, J., de Dios-Anton, F., Colmenarejo, G.,
Valle, S.G., Marco, M., Fiandor, J.M., Martin, J.J., Steel, P.G., Denny, P.W., 2018.
Identifying inhibitors of the Leishmania inositol phosphorylceramide synthase with
antiprotozoal activity using a yeast-based assay and ultra-high throughput screening
platform. Sci. Rep. 8, 3938.
Odom, A.R., Stahlberg, A., Wente, S.R., York, J.D., 2000. A role for nuclear inositol 1,4,5-
trisphosphate kinase in transcriptional control. Science 287, 2026–2029.
Oghumu, S., Satoskar, A.R., 2013. PI3K-gamma inhibitors in the therapeutic intervention
of diseases caused by obligate intracellular pathogens. Commun. Integr. Biol. 6,
e23360.
Ogretmen, B., Hannun, Y.A., 2004. Biologically active sphingolipids in cancer patho-
genesis and treatment. Nat. Rev. Canc. 4, 604–616.
Pulfer, M., Murphy, R.C., 2003. Electrospray mass spectrometry of phospholipids. Mass
Spectrom. Rev. 22, 332–364.
Rabionet, M., Bayerle, A., Marsching, C., Jennemann, R., Grone, H.J., Yildiz, Y., Wachten,
D., Shaw, W., Shayman, J.A., Sandhoff, R., 2013. 1-O-acylceramides are natural
components of human and mouse epidermis. J. Lipid Res. 54, 3312–3321.
Reithinger, R., Dujardin, J.C., Louzir, H., Pirmez, C., Alexander, B., Brooker, S., 2007.
Cutaneous leishmaniasis. Lancet Infect. Dis. 7, 581–596.
Reynolds, T.B., 2009. Strategies for acquiring the phospholipid metabolite inositol in
pathogenic bacteria, fungi and protozoa: making it and taking it. Microbiology 155,
1386–1396.
Rodriguez, A.M., Graef, A.J., LeVine, D.N., Cohen, I.R., Modiano, J.F., Kim, J.H., 2015.
Association of sphingosine-1-phosphate (S1P)/S1P receptor-1 pathway with cell
proliferation and survival in canine hemangiosarcoma. J. Vet. Intern. Med. 29,
1088–1097.
Sasaki, T., Takasuga, S., Sasaki, J., Kofuji, S., Eguchi, S., Yamazaki, M., Suzuki, A., 2009.
Mammalian phosphoinositide kinases and phosphatases. Prog. Lipid Res. 48,
307–343.
Serrano, A.A., Schenkman, S., Yoshida, N., Mehlert, A., Richardson, J.M., Ferguson, M.A.,
1995. The lipid structure of the glycosylphosphatidylinositol-anchored mucin-like
sialic acid acceptors of Trypanosoma cruzi changes during parasite differentiation
from epimastigotes to infective metacyclic trypomastigote forms. J. Biol. Chem. 270,
27244–27253.
Seyfang, A., Kavanaugh, M.P., Landfear, S.M., 1997. Aspartate 19 and glutamate 121 are
critical for transport function of the myo-inositol/H+ symporter from Leishmania
donovani. J. Biol. Chem. 272, 24210–24215.
Seyfang, A., Landfear, S.M., 1999. Substrate depletion upregulates uptake of myo-inositol,
glucose and adenosine in Leishmania. Mol. Biochem. Parasitol. 104, 121–130.
Seyfang, A., Landfear, S.M., 2000. Four conserved cytoplasmic sequence motifs are im-
portant for transport function of the Leishmania inositol/H(+) symporter. J. Biol.
Chem. 275, 5687–5693.
Shayman, J.A., 2000. Sphingolipids. Kidney Int. 58, 11–26.
Smith, E.R., Merrill, A.H., Obeid, L.M., Hannun, Y.A., 2000. Effects of sphingosine and
other sphingolipids on protein kinase C. Methods Enzymol. 312, 361–373.
Sutterwala, S.S., Hsu, F.F., Sevova, E.S., Schwartz, K.J., Zhang, K., Key, P., Turk, J.,
Beverley, S.M., Bangs, J.D., 2008. Developmentally regulated sphingolipid synthesis
in African trypanosomes. Mol. Microbiol. 70, 281–296.
Tirodkar, T.S., Voelkel-Johnson, C., 2012. Sphingolipids in apoptosis. Exp. Oncol. 34,
231–242.
Trinconi, C.T., Reimao, J.Q., Bonano, V.I., Espada, C.R., Miguel, D.C., Yokoyama-
Yasunaka, J.K., Uliana, S.R., 2017. Topical tamoxifen in the therapy of cutaneous
leishmaniasis. Parasitology 1–7.
Trinconi, C.T., Reimao, J.Q., Coelho, A.C., Uliana, S.R., 2016. Efficacy of tamoxifen and
miltefosine combined therapy for cutaneous leishmaniasis in the murine model of
infection with Leishmania amazonensis. J. Antimicrob. Chemother. 71, 1314–1322.
Trinconi, C.T., Reimao, J.Q., Yokoyama-Yasunaka, J.K., Miguel, D.C., Uliana, S.R., 2014.
Combination therapy with tamoxifen and amphotericin B in experimental cutaneous
leishmaniasis. Antimicrob. Agents Chemother. 58, 2608–2613.
Vince, J.E., Tull, D., Landfear, S., McConville, M.J., 2011. Lysosomal degradation of
Leishmania hexose and inositol transporters is regulated in a stage-, nutrient- and
ubiquitin-dependent manner. Int. J. Parasitol. 41, 791–800.
Wang, H., Charles, A.G., Frankel, A.J., Cabot, M.C., 2003. Increasing intracellular cer-
amide: an approach that enhances the cytotoxic response in prostate cancer cells.
Urology 61, 1047–1052.
WHO, 2010. Control of the Leishmaniasis: Report of a Meeting of the World Health
Organization Expert Committee on the Control of Leishmaniases, WHO Technical
Report Series. WHO, Geneva.
Yoneyama, K.A., Tanaka, A.K., Silveira, T.G., Takahashi, H.K., Straus, A.H., 2006.
Characterization of Leishmania (Viannia) braziliensis membrane microdomains, and
their role in macrophage infectivity. J. Lipid Res. 47, 2171–2178.
Zhang, K., Hsu, F.F., Scott, D.A., Docampo, R., Turk, J., Beverley, S.M., 2005. Leishmania
salvage and remodelling of host sphingolipids in amastigote survival and acid-
ocalcisome biogenesis. Mol. Microbiol. 55, 1566–1578.
C.T. Trinconi et al. IJP: Drugs and Drug Resistance 8 (2018) 475–487
487
